Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies’ new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug’s monthly cost from a list price of around $606 to $346. But the discounted price of Eliquis is still more than nine times the average monthly out-of-pocket cost paid by patients who are commercially insured, and significantly higher than Medicare’s new negotiated price for the drug under the Inflation Reduction Act. George Frey | Reuters
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount.
The move comes as the Trump administration ramps up pressure on the